The endothelin receptor antagonist CPU0213 is more effective than aminoguanidine to attenuate isoproterenol-induced vascular abnormality by suppressing overexpression of NADPH oxidas, ETA, ETB, and MMP9 in the vasculature

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 1, 2008, Pages 42-48

  Xu, Jin ^a   Li, Na ^a   Dai, De Zai ^a   Yu, Feng ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CPU0213; Endothelin receptor antagonist; MMP9; NAPDH oxidase; Oxidative stress

Indexed keywords

ACETYLCHOLINE; AMINOGUANIDINE; CPU 0213; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOPRENALINE; MESSENGER RNA; PHENYLEPHRINE; PROTEIN PHOX22; PROTEIN PHOX47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG; CPU0213; GUANIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME REGULATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; VASCULAR DISEASE; VASCULARIZATION; VASODILATATION; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; MUSCLE CONTRACTION; MUSCLE RELAXATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; GUANIDINES; ISOPROTERENOL; MATRIX METALLOPROTEINASE 9; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NADPH OXIDASE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RNA, MESSENGER; UP-REGULATION;

EID: 55949133542     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817dfc8f     Document Type: Article

References (38)

1. Oltman CL, Kleinschmidt TL, Davidson EP, et al. Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes. Vascul Pharmacol. 2008;48:47-53.
2. Nitenberg A. Hypertension, endothelial dysfunction and cardiovascular risk. Arch Mal Coeur Vaiss. 2006;99:915-921.
3. Heymes C, Bendall JK, Ratajczak P, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol. 2003;41:2164-2171.
4. Zhang GX, Ohmori K, Nagai Y, et al. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol. 2007;42:804-811.
5. Brouri F, Hanoun N, Mediani O, et al. Blockade of ß1- and desensitization of ß2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004;485:227-234.
6. Bleeke T, Zhang H, Madamanchi N, et al. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res. 2004;94:37-45.
7. Li L, Watts SW. Endothelin-1 increases vascular superoxide via endothelin A-NADPH oxidase pathway in low-rein hypertension. Circulation. 2003;107:1053-1058.
8. Wilton E, Bland M, Thompson M, et al. Matrix metalloproteinase expression in the ascending aorta and aortic valve. Interact Cardiovasc Thorac Surg. 2008;7:37-40.
9. Moon SK, Kang SK, Kim CH. Reactive oxygen species mediates disialoganglioside GD3-induced inhibition of ERK1/2 and matrix metalloproteinase-9 expression in vascular smooth muscle cells. FASEB J. 2006; 20:1387-1395.
10. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. 2006;113:1708-1714.
11. Kähler J, Mendel S, Weckmüller J, et al. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol. 2000;32:1429-1437.
12. Laplante MA, Wu R, Moreau P, et al. Endothelin mediates superoxide production in angiotensin II-induced hypertension in rats. Free Radic Biol Med. 2005;38:589-596.
13. Dong F, Zhang X, Wold LE, et al. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323-333.
14. B of compound 0213 (Chinese). J China Pharmac Univ. 2004;35:552-557
15. Su W, Dai DZ, Liu HR, et al. Upregulated endothelin system in diabetic vascular dysfunction and early retinopathy is reversed by CPU0213 and total triterpene acids from fructus corni. Clin Exp Pharmacol Physiol. 2007;34:1228-1233.
16. Na T, Dai DZ, Tang XY, et al. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol. 2007;375:39-49.
17. He HB, Yuan SH, Dai DZ, et al. Nonselective endothelin receptor antagonist CPU0213 improves the septic shock induced impairment of vascular activity by suppressing ET system and NFKB in rats (Chinese). Chin J Clin Ther J. 2006;11:145-152.
18. Yuan SH, Dai DZ, Guan L, et al. CPU0507 an endothelin receptor antagonist improves rat hypoxic pulmonary artery hypertension and constriction in vivo and in vitro. Clin Exp Pharmacol Physiol. 2006;33: 1066-1072.
19. Ratto E, Leoncini G, Viazzi F, et al. Ambulatory arterial stiffness index and renal abnormalities in primary hypertension. J Hypertens. 2006;24: 2033-2038.
20. Trautner S, Amtorp O, Boesgaard S, et al. Ca(2+) sensitisation of force production by noradrenaline in femoral conductance and resistance arteries from rats with postinfarction congestive heart failure. Vascul Pharmacol. 2006;44:156-165.
21. Ding H, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag. 2005;1:55-71.
22. San Martin A, Foncea R, Laurindo FR, et al. Nox1-based NADPH oxidase-derived superoxide is required for VSMC activation by advanced glycation end-products. Free Radic Biol Med. 2007;42:1671-1679.
23. Gupte RS, Vijay V, Marks B, et al. Upregulation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase activity increases oxidative stress in failing human heart. J Card Fail. 2007;13:497-506.
24. Zhang GX, Kimura S, Nishiyama A, et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res. 2005;65:230-238.
25. Manea A, Manea SA, Gafencu AV, et al. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch Physiol Biochem. 2007;113:163-172.
26. Xia HJ, Dai DZ, Dai Y. Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci. 2006;79:1812-1819.
27. Cai H. Hydrogen peroxide regulation of endothelial function: Origins, mechanisms, and consequences. Cardiovasc Res. 2005;68:26-36.
28. Fontayne A, Dang PM, Gougerot-Pocidalo MA, et al. Phosphorylation of p47phox sites by PKC alpha, beta II, delta, and zeta: effect on binding to p22phox and on NADPH oxidase activation. Biochemistry. 2002;41: 7743-7750.
29. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478.
30. An SJ, Boyd R, Zhu M, et al. NADPH oxidase mediates angiotensin IIinduced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res. 2007;75:702-709.
31. Lalu MM, Cena J, Chowdhury R, et al. Matrix metalloproteinases contribute to endotoxin and interleukin-1beta induced vascular dysfunction. Br J Pharmacol. 2006;49:31-42.
32. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90: 251-262.
33. Liu Q, Ji M, Dai DZ. Thyroxin induces ventricular hypertrophy accompanying changes in MMPs which are regulated by a novel endothelin receptor antagonist CPU0213 (Chinese). J China Pharm Univ. 2004;35: 150-155
34. Feng Y, Tang XY, Dai DZ, et al. Reversal of isoproterenol-induced downregulation of phospholamban and FKBP12.6 by CPU0213-mediated antagonism of endothelin receptors. Acta Pharmacol Sin. 2007;28:1746-1754.
35. Doǧru-Abbasoǧlu S, Balkan J, Kanbaǧli O, et al. Aminoguanidine, an inducible nitric oxide synthase inhibitor, plus N-acetylcysteine treatment reduce the lipopolysaccharide-augmented hepatotoxicityin rats with cirrhosis. Hum Exp Toxicol. 2002;21:359-364.
36. Soulis T, Sastra S, Thallas V, et al. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia. 1999;42:472-479.
37. Stadler K, Jenei V, Somogyi A, et al. Aminoguanidine prevents peroxynitrite production and cardiac hypertrophy in streptozotocin-induced diabetic rats. Orv Hetil. 2004;145:2491-2496.
38. Li D, Qu Y, Tao L, et al. Inhibition of iNOS protects the aging heart against beta-adrenergic receptor stimulation-induced cardiac dysfunction and myocardial ischemic injury. J Surg Res. 2006;131:64-72.